EZH2 and myelodysplastic syndrome: Furthermore, the antiproliferative effect of bafilomycin A1 10 nM did not differ between patients with and without MDS-related mutations (i.e., ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1 orZRSR2) (Table S3) [2,57].